Cedric Bisson has been a director of Allostera since 2009.

Dr. Bisson is the partner in charge of life sciences and energy investments at iNovia Capital. He leads investments in those sectors with a focus on biopharmaceuticals, medical devices and electric energy. Prior to joining iNovia in 2003, Dr. Bisson was an associate principal at McKinsey & Company, a leading global management consulting firm, where he co-led the Canadian healthcare (including pharma, biotech and private equity) and innovation practices; during this time, he also pursued extensive professional activities in Montréal, New York City and Paris in pharmaceutical and medical devices. Dr. Bisson currently serves or has served as a board member to Iaculor Injection, Milestone Pharmaceuticals, Mimetogen Pharmaceuticals and Resonant Medical. He is an active member of many life sciences initiatives in Canada and abroad, and is also a member of the boards of BIOQuebec (Québec’s life sciences industry association) and Procure (a non-profit charity against prostate cancer).

Dr. Bisson obtained an M.D. degree from McGill University and a J.D. (law) degree from Université de Montréal.

Ms. Borenstein has 20 years of management, entrepreneurial and consulting experience in the Biopharmaceutical industry.Prior to joining BDC, she was Chief Operating Officer, VP of Regulatory Affairs and Product Strategy and VP of Clinical and Regulatory Affairs for biotech companies as well as Senior Vice President of Scientific Affairs for a public pharmaceutical company. Ela's diversified background includes senior management responsibilities in drug and medical device development, key involvement in product acquisition and M&A activities including a business development role and building multi-disciplinary teams involved in all aspects of research and product development. Ela holds a B.Sc. Chemistry Honours from University of Western Ontario, a M.Sc. in Pharmacology from University of Toronto and an MBA in Bio-Industries from UQAM.

Isabelle Dufresne has been a director of Allostera since 2009.

Ms. Dufresne brings a wealth of experience in corporate finance, strategic intellectual property management, and technology transfer in the life sciences domain. She has served for more than seven years as a Director of Investments at the Centre quebecois de valorisation des biotechnologies (CQVB), a technology transfer center that aims to stimulate and support technology transfer and innovation within bio-industry companies in Quebec. Additionally, she is affiliated with the Fonds Bio-Innovation, a venture capital fund that supports early-stage and Quebec-based biotechnology companies. Before joining the CQVB, Ms. Dufresne spent two years as Project Manager for Development and Technology Transfer at SOVAR, one of four university research valorization entities whose mission is to commercialize discoveries made by researchers at Laval University and CHUQ (Centre hospitalier universitaire de Québec). She has participated in the start-up and growth phase of several innovative life sciences companies, including those focused on human health, animal health, nutraceuticals, industrial enzymes and recombinant proteins.

Ms. Dufresne holds Masters degrees in both microbiology/immunology (MSc) and pharmaceutical management (MBA) from Laval University and a bachelor degree in medical Biology from Université du Québec à Trois-Rivières (UQTR). Prior to her MBA, she also worked in Canada's largest infectiology research lab (CRI-CHUL) as a research assistant. Currently, Ms Dufresne is a member of several boards of directors and scientific advisory boards of CQVB/Fonds-Bionnovation portfolio companies.

Jamie Stiff has been a director of Allostera since 2009.

He joined Genesys Capital in 2002 and became partner at the firm in 2007. He brings to Genesys a unique combination of scientific understanding and business acumen and has demonstrated an innate affinity for the business of venture capital. Since joining the firm, Mr. Stiff has gained significant deal experience across a number of transactions. Mr. Stiff currently sits as an observer on the board of NeurAxon Inc. Past board roles include directorships at Matregen Corp. and Stempath Inc. and board observer at Zelos Therapeutics and Interface Biologics. Prior to joining Genesys, Mr. Stiff worked at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in the genetic diagnostics arena. This experience combined with an academic background in biology has provided significant technical knowledge of many areas of life sciences and provides for a keen eye for sourcing promising early stage deal flow through the company’s proprietary Technology Access Partnerships.

Mr. Stiff holds a Bachelor of Science (Honours) in Biology from Queen’s University and an MBA from the Rotman School of Management at the University of Toronto.

Dr. Bogdan Dziurzynski has been a director of Allostera since 2009.

Dr. Dziurzynski is a strategic planning and regulatory management consultant. In addition to the board of Allostera, he serves as an independent member of the Board of Directors of Dendreon Corporation in Seattle, Washington, and the Biologics Consulting Group in Alexandria, Virginia and is on the business advisory board of Integrated Biotherapeutics, Inc. in Germantown, Maryland. He is a Fellow of the Regulatory Affairs Professional Society and a past President and Chairman of the Board. The Society creates and upholds standards of ethics, credentialing and education for the regulatory affairs profession within the health product sector and represents over 11,000 individuals worldwide from governments, corporations, academia, research and nonprofit organizations.

His career spanning over thirty six years includes regulatory experience in clinical research design and execution, biopharmaceutical product development and manufacture, production facility design and validation, product advertising and promotion, post-market drug safety surveillance, quality assurance and quality control. He served as a senior vice-president with MedImmune, Inc., a vice-president with Immunex Corporation and has held management positions with Genetic Systems, Inc., C.R. Bard, Inc., and Johnson and Johnson’s Ortho Diagnostics Division.

He holds a Doctorate in Public Administration, an MBA in Marketing and Management, and undergraduate degrees in Psychology and Laboratory Technology.

Jean-Paul Castaigne has been a director of Allostera since 2006.

Dr. Castaigne is currently the CEO of AngioChem, a biotechnology company in Montreal. He has extensive international experience in the pharmaceutical and biotech industry. Prior to joining AngioChem as CEO, he was COO and CSO of Conjuchem, and previously he was Vice President, Head of Global R&D at the Fournier Group in France. In addition, Dr. Castaigne spent eleven years with Novartis in a variety of management positions, including Corporate Vice President for Canada, President and Managing Director in the Philippines and Director of Medical and R&D in France. Dr. Castaigne has also worked with CILAG (J&J) and Sanofi in France. He received his MD from Paris University in 1975 and held the position of Associate Professor of oncology and pneumology in 1978.

Dr. Castaigne received an MBA from HEC Paris in 1987. Dr. Castaigne is member of the board of the three following biotech companies: Tranzyme Pharma, Asmacure and Allostera.

Mark Kaufmann has been a director of Allostera since 2009 and currently serves as Allostera’s President and CEO.

Mr. Kaufmann has nearly 20 years of experience in the biopharmaceutical industry in both the U.S. and Canada. Prior to joining Allostera, Mr. Kaufmann was President and CEO of Celmed BioSciences where he was responsible for raising funds and selling the company in a deal worth over $40M to a European biotechnology company, Kiadis Pharma. Prior to his role as CEO, he was Chief Operating Officer at Celmed with responsibility for the operations and corporate development of the Company including the progression of Celmed's three products into Phase I/II human clinical testing, the development of a new business plan for Celmed and its early merger with NewBiotics Inc. Prior to joining Celmed, Mr. Kaufmann was Vice-President Corporate Development at Nexia Biotechnologies Inc. in Montreal where he was responsible for building Nexia's biopharmaceutical business, including product development and licensing agreements. He was previously Chief Financial Officer of Conceptis Technologies Inc., a medical media and education company, and prior to that, Mr. Kaufmann worked for five years with MedImmune, Inc, located in Maryland, as Director of Planning and Analysis where he led the strategic planning and contributed to the development of MedImmune's commercialization strategy.

Mr. Kaufmann holds an MBA from the University of Michigan School of Business and a BA in Biochemical Sciences from Harvard University.